[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-514356-105":59,"doc-detail-514356-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","euroguiderm-evidence-based-guideline-for-the-treatment-of-acne-long-version","EuroGuiDerm Evidence-based Guideline for the Treatment of Acne - long version","","EuroGuiDerm Evidence-based Guideline for the Treatment of Acne – long version (ICD L70.0, L70.1) provides an updated 2025 evidence-based framework for clinical management. The guideline covers objectives, target population, pharmacoeconomic and vehicle considerations for topical therapy, and clinical features across acne variants. It details assessment and comparability of outcomes, including acne grading and prognostic factors affecting treatment choice, while addressing epidemiology and pathophysiology. It also specifies methods for assessing evidence, including risk of bias and methodological quality.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/euroguiderm-evidence-based-guideline-for-the-treatment-of-acne-long-version/514356/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/euroguiderm-evidence-based-guideline-for-the-treatment-of-acne-long-version/514356.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What topics does the EuroGuiDerm acne guideline cover in this long version?","Question",{"text":113,"@type":114},"It covers guideline objectives and target population, pharmacoeconomic and topical vehicle considerations, clinical features across acne variants, and factors influencing treatment choice. It also includes outcome assessment methods, epidemiology/pathophysiology, and evidence-assessment methodology with risk of bias.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the guideline suggest assessing acne severity and prognosis?",{"text":118,"@type":114},"It addresses acne grading systems and highlights prognostic factors that should influence treatment choice, including factors related to disease severity and how assessment of scarring potential informs disease management.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence-assessment approach is described?",{"text":122,"@type":114},"The guideline specifies methods for assessing evidence, including evaluation of risk of bias and methodological quality, with an update noted for 2025.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},514356,1791487585,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":11,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","EuroGuiDerm Evidence-based  \nGuideline for the Treatment of Acne –  \nlong version  \n(ICD L70.0, L70.1)  \nUpdate 2025  \nLong version  \nExpiry date:  \nJune 2030  \nA. Nast 1 , B. Al Wattar2,3 , M. Beylot Barry4 , H. Brüggemann5 , Z. Bukvić Mokos6 , D. M. Caruana7 , K. Degitz8 , C. Dessinioti9 , B. Dréno 10 , R.J. B Driessen 11 , H. Gollnick 12 , M. Hædersdal13 , A. Katoulis 14 , S. Läuchli15 , J. Lambert 16 , A. M. Layton17,18 , G. Micali 19 , F. Ochsendorf20 , T. Sathyapalan21 , K.Z. Stangeland22 , S. F. Thomsen23 , D. Töröcsik24 , A. Pennitz1  \n1 Division of Evidence-Based Medicine, Klinik für Dermatologie, Charité - Universitätsmedizin Berlin, Berlin, Germany  \n2 Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.  \n3 Beginnings Assisted Conception Unit, Epsom and St Helier University Hospitals, London, UK.  \n4 Dermatology Department, CHU Bordeaux, Bordeaux, France, Université de Bordeaux, Bordeaux, France  \n5 Department of Biomedicine, Aarhus University, 8000 Aarhus Centrum, Denmark  \n6 Department of Dermatology and Venereology, University Hospital Centre Zagreb, University of Zagreb School of Medicine , Zagreb, Croatia  \n7 Private practice, Malta  \n8 Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany  \n9 Department of Dermatology, University of Athens, Andreas Sygros Hospital , Greece  \n10 Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001 . F-44000 Nantes, France  \n11 Department of Dermatology , Radboud university medical center, Nijmegen, The Netherlands  \n12 Department of Dermatology and Venereology, University of Magdeburg, Magdeburg, Germany  \n13 Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark  \n14 Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, \"Attikon\" General University Hospital, Athens, Greece  \n15 Institute of Dermatology and Venerology, Stadtspital Zürich  \n16 Department of Dermatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium  \n17 Skin Research Centre, Hull York Medical School, University of York, UK  \n18 Department of Dermatology, Harrogate and District NHS Trust, Harrogate, UK  \n19 Department of Dermatology, University of Catania, Sicily, Italy  \n20 Goethe-University Frankfurt, Universitätsmedizin, Department of Dermatology, Venereology and Allergology, Frankfurt, Germany  \n21 Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK  \n22 Department of Dermatology and Venereology, Aleris Stavanger, Stavanger, Norway  \n23 Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark  \n24 Department of Dermatology, Faculty of Medicine, University of Debrecen and ELKH-DE Allergology Research Group, Debrecen, Hungary  \nTable of contents  \nEuroGuiDerm Evidence-based........................................................................ II  \nGuideline for the Treatment of Acne – long version ..................................... II  \n1 Disclaimer .................................................................................................. 1  \n2 Introduction ............................................................................................... 3  \n2.1 Objectives of the guideline ............................................................................................. 3  \n2.2 Target population............................................................................................................ 5  \n2.3 Pharmacoeconomic considerations ............................................................................... 5  \n2.4 Considerations with respect to vehicle for topical treatments ........................................ 6  \n2.5 Considerations regarding area of involvement........................................","cbCaiigeh9alIGBR","https://ap.wps.com/l/cbCaiigeh9alIGBR","pdf",2050802,"English","# Disclaimer\n# Introduction\n## Objectives of the guideline\n## Target population\n## Pharmacoeconomic considerations\n## Considerations with respect to vehicle for topical treatments\n## Considerations regarding area of involvement\n## Clinical features and variants\n### Comedonal acne\n### Papulopustular acne\n### Nodular/ conglobate acne\n### Other acne variants\n# Assessment, comparability of treatment outcomes\n## Acne grading\n### Acne grading systems\n## Prognostic factors that should influence treatment choice\n### Prognostic factors of disease severity\n### Influence of scarring assessment on disease management\n# Epidemiology and pathophysiology\n## Epidemiology\n## Pathophysiology\n# Methods-Assessment of evidence\n## Risk of bias and methodological quality (update 2025)","[{\"question\":\"What topics does the EuroGuiDerm acne guideline cover in this long version?\",\"answer\":\"It covers guideline objectives and target population, pharmacoeconomic and topical vehicle considerations, clinical features across acne variants, and factors influencing treatment choice. It also includes outcome assessment methods, epidemiology/pathophysiology, and evidence-assessment methodology with risk of bias.\"},{\"question\":\"How does the guideline suggest assessing acne severity and prognosis?\",\"answer\":\"It addresses acne grading systems and highlights prognostic factors that should influence treatment choice, including factors related to disease severity and how assessment of scarring potential informs disease management.\"},{\"question\":\"What evidence-assessment approach is described?\",\"answer\":\"The guideline specifies methods for assessing evidence, including evaluation of risk of bias and methodological quality, with an update noted for 2025.\"}]","EuroGuiDerm Evidence-based Guideline for the Treatment of Acne - long version | PDF",1791298798,227]